Literature DB >> 12651911

Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.

Li Jia1, Joshua Kim, Howard Shen, Peter E Clark, Wayne D Tilley, Gerhard A Coetzee.   

Abstract

Ligand-activated androgen receptors (ARs) occupy target genes and recruit histone modifiers that influence transcriptional competency. In LNCaP prostate cancer cells, the natural ligand 5alpha-dihydrotestosterone (DHT) activates transiently transfected AR-responsive promoter constructs; concurrent treatment with the protein kinase A activator forskolin enhanced AR stimulation induced by DHT. Additional treatment with the cytokine IL-6, purportedly an AR activator, markedly inhibited receptor activity. To assess AR activity on natural chromatin-integrated promoters/enhancers, we determined AR occupancy of the endogenous prostate specific antigen (PSA) promoter/enhancer as well as PSA expression in LNCaP cells treated with DHT; AR occupancy of the PSA enhancer was rapid (within 1 h of stimulation), robust (10-fold over background), and sustained (8-16 h). In contrast, AR occupancy of the PSA promoter was only increased by 2-fold. Histone H3 acetylation at both the enhancer and promoter was evident 1-2 h after DHT treatment. Detectable pre- and mature PSA mRNA levels appeared after 1 and 6 h treatment, respectively. Substantial qualitative and quantitative differences in PSA expression and AR occupancy of the PSA enhancer were observed when DHT-induced and ligand-independent activations of the AR were compared; forskolin stimulated PSA mRNA and protein expression, whereas IL-6 inhibited both DHT- and forskolin-stimulated expression. IL-6 did not diminish DHT-dependent AR occupancy of the PSA enhancer but inhibited CBP/p300 recruitment, histone H3 acetylation, and cell proliferation. These findings provide a contextual framework for interpreting the contribution of non-steroidal activation of the AR to signaling in vivo, and have implications for prostate cancer cell growth.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651911

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  22 in total

Review 1.  The role of HER2 in cancer therapy and targeted drug delivery.

Authors:  Wanyi Tai; Rubi Mahato; Kun Cheng
Journal:  J Control Release       Date:  2010-04-10       Impact factor: 9.776

2.  Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells.

Authors:  Claudia Andreu-Vieyra; John Lai; Benjamin P Berman; Baruch Frenkel; Li Jia; Peter A Jones; Gerhard A Coetzee
Journal:  Mol Cell Biol       Date:  2011-10-03       Impact factor: 4.272

3.  Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells.

Authors:  Li Jia; Howard C Shen; Marcus Wantroba; Omar Khalid; Gangning Liang; Qingcai Wang; Elisabet Gentzschein; Jacek K Pinski; Frank Z Stanczyk; Peter A Jones; Gerhard A Coetzee
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

4.  Enhancement of gene transactivation activity of androgen receptor by hepatitis B virus X protein.

Authors:  Yanyan Zheng; Wen-Ling Chen; W-L Maverick Ma; Chawnshang Chang; J-H James Ou
Journal:  Virology       Date:  2007-02-28       Impact factor: 3.616

5.  The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy.

Authors:  Tyler Etheridge; Jinning Liou; Tracy M Downs; E Jason Abel; Kyle A Richards; David F Jarrard
Journal:  Am J Clin Exp Urol       Date:  2018-06-15

6.  Progressive recruitment of Runx2 to genomic targets despite decreasing expression during osteoblast differentiation.

Authors:  Steven Pregizer; Sanjeev K Baniwal; Xiting Yan; Zea Borok; Baruch Frenkel
Journal:  J Cell Biochem       Date:  2008-11-01       Impact factor: 4.429

7.  The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer.

Authors:  Mark M Pomerantz; Nasim Ahmadiyeh; Li Jia; Paula Herman; Michael P Verzi; Harshavardhan Doddapaneni; Christine A Beckwith; Jennifer A Chan; Adam Hills; Matt Davis; Keluo Yao; Sarah M Kehoe; Heinz-Josef Lenz; Christopher A Haiman; Chunli Yan; Brian E Henderson; Baruch Frenkel; Jordi Barretina; Adam Bass; Josep Tabernero; José Baselga; Meredith M Regan; J Robert Manak; Ramesh Shivdasani; Gerhard A Coetzee; Matthew L Freedman
Journal:  Nat Genet       Date:  2009-06-28       Impact factor: 38.330

8.  Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase.

Authors:  Irina U Agoulnik; William E Bingman; Manjula Nakka; Wei Li; Qianben Wang; X Shirley Liu; Myles Brown; Nancy L Weigel
Journal:  Mol Endocrinol       Date:  2008-09-11

9.  MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.

Authors:  T Sun; X Wang; H H He; C J Sweeney; S X Liu; M Brown; S Balk; G-Sm Lee; P W Kantoff
Journal:  Oncogene       Date:  2013-06-17       Impact factor: 9.867

10.  Functional enhancers at the gene-poor 8q24 cancer-linked locus.

Authors:  Li Jia; Gilad Landan; Mark Pomerantz; Rami Jaschek; Paula Herman; David Reich; Chunli Yan; Omar Khalid; Phil Kantoff; William Oh; J Robert Manak; Benjamin P Berman; Brian E Henderson; Baruch Frenkel; Christopher A Haiman; Matthew Freedman; Amos Tanay; Gerhard A Coetzee
Journal:  PLoS Genet       Date:  2009-08-14       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.